A significant role of lipogenic enzymes in colorectal cancer

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2585-2590

  Notarnicola, Maria ^a   Messa, Caterina ^a   Caruso, Maria Gabriella ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Cell growth; Colorectal cancer; Farnesyl diphosphate synthase; Farnesyltransferase; Fatty acid synthase; Lipoprotein lipase; Review

Indexed keywords

ACETYL COENZYME A SYNTHETASE; ALENDRONIC ACID; FATTY ACID SYNTHASE; GERANYLTRANSFERASE; K RAS PROTEIN; LIPOPROTEIN; LIPOPROTEIN LIPASE; MALONYL COENZYME A; MESSENGER RNA; OLIVE OIL; PAMIDRONIC ACID; POLYPHENOL; PROTEIN FARNESYLTRANSFERASE; PROTEIN P53; TRIACYLGLYCEROL;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; ENZYME DEGRADATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; LIPID METABOLISM; MOLECULARLY TARGETED THERAPY; NONHUMAN; OSTEOLYSIS; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PRENYLATION; REVIEW;

ALKYL AND ARYL TRANSFERASES; COLORECTAL NEOPLASMS; FARNESYLTRANSTRANSFERASE; FATTY ACID SYNTHETASE COMPLEX; HUMANS; LIPID METABOLISM; LIPOPROTEIN LIPASE;

EID: 84865689783     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Fearon ER and Vogelstein A: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
2. Srivastava S, Verma M and Henson DE: Biomarkers for early detection of colon cancer. Clinical Cancer Res 7: 1118-1126, 2001. (Pubitemid 32708660)
3. Rao KN: The significance of cholesterol biosynthetic pathway in cell growth and carcinogenesis. Anticancer Res 15: 309-314, 1995.
4. Newmark HL: Squalene, olive oil, and cancer risk. Review and hypothesis. Ann NY Acad Sci 889: 193-203, 1999.
5. Krisans SK, Ericsson J, Edwards PA and Keller GA: Farnesyl-diphosphate synthase is localized in peroxisomes. J Biol Chem 269: 14165-14169, 1994. (Pubitemid 24191174)
6. Clarke S: Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem 61: 355-386, 1992.
7. Farnsworth CC, Wolda SL, Gelb MH and Glomset JA: Human lamin B contains a farnesylated cysteine residue. J Biol Chem 264: 20422-20429, 1989. (Pubitemid 20009228)
8. Sinensky M, Famtle K, Triyillo M, McLain T, Kupfer A and Dalton M: The processing pathway of prelamin A. J Cell Sci 107: 61-67, 1994. (Pubitemid 24039034)
9. Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR and Kirschmeier P: FTIs block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275: 30451-30457, 2000.
10. Zeng Q, Si X, Horstmann H, Xu Y, Hong W and Pallen CJ: Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome. J Biol Chem 275: 21444-21452, 2000. (Pubitemid 30481847)
11. Reiss Y, Seabra MC, Armstrong SA, Slaughter CA, Goldstein JL and Brown MS: Non-identical subunits of p21 Ras-farnesyl-transferase: peptide binding and farnesylpirophosphate carrier functions. J Biol Chem 266: 10672-10677, 1991. (Pubitemid 21906854)
12. Reiss Y, Goldstein JL, Seabra MC, Casey P and Brown MS: Inhibition of purified p21 ras farnesyl protein transferase by cys-AAX tetrapeptides. Cell 62: 81-88, 1990.
13. Manne V, Roberts D, Tobin A, O'Rourke E, De Virgilio M, Meyers C, Ahmed N, Kurz B, Resh M, Kung HF and Barbacid M: Identification and preliminary characterization of protein-cysteine farnesyltransferase. Proc Natl Acad Sci USA 87: 7541-7545, 1990. (Pubitemid 20341752)
14. Agarwal R, Khan SG, Athar M, Zaidi SY, Bichers DR and Mukhtar H: Ras protein p21 processing enzyme farnesyltransferase in chemical carcinogen-induced murine skin tumors. Mol Carcinog 8: 290-298, 1993.
15. Downward J: RAS signaling and apoptosis. Curr Opin Genet Dev 8: 49-54, 1998.
16. Bos J: RAS oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989.
17. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE and Der CJ: Isoprenoid addition to ras proteins is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89: 6403-6407, 1992.
18. Rowinsky EK, Windle JJ and Von Hoff DD: RAS protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17: 3631-3652, 1999. (Pubitemid 29517936)
19. Reuter CW, Morgan MA and Bergmann L: Targeting the RAS signaling pathway: a rational mechanism-based treatment for hematologic malignancies? Blood 96: 1655-1669, 2000. (Pubitemid 30661043)
20. Lebowitz PF, Casey PJ, Prendergast GC and Thissen JA: Farnesyl-transferase inhibitors is mediated by gain of geranylgeranylated Rho B. J Biol Chem 272: 15591-15594, 1997.
21. Du W, Lebowitz PF and Prendergast GC: Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated Rho B. Mol Cell Biol 19: 1831-1834, 1999.
22. Khan SG, Dummer R, Siddiqui J, Bickers DR, Agarwal R and Mukhtar H: Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas. Biochem Biophys Res Comm 220: 795-801, 1996. (Pubitemid 26198590)
23. Tanimoto H, Mehta KD, Parmley TH, Shigemasa K, Parham GP, Clarke J and O'Brien TJ: Expression of the farnesyltransferase beta-subunit gene in human ovarian carcinoma: correlation to K-RAS mutation. Gynecol Oncol 66: 308-312, 1997. (Pubitemid 27335422)
24. Caruso MG, Notarnicola M, Bifulco M, Laezza C, Guerra V, Altomare DF, Memeo V, Lorusso D, Demma I and Di Leo A: Increased farnesyltransferase activity in human colorectal cancer: relationship with clinicopathological features and K-RAS mutation. Scand J Gastroenterol 38: 80-85, 2003. (Pubitemid 36152869)
25. Faust JR, Brown MS and Goldstein JL: Synthesis of Isopentenyl tRNA from mevalonate in cultured human fibroblasts. J Biol Chem 255: 6546-6548, 1980.
26. Eskens F, Awada A, Verweig J, Cutler DL, Hanauske A and Piccart M: Phase I and pharmacocinetic study of the oral Ftase inhibitor SCH66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 19: 1167-1175, 2001. (Pubitemid 32176295)
27. Zujewski BJ, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB and Cowan KH: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18: 927-941, 2000. (Pubitemid 30106625)
28. Fitton A and Mc Tavish D: Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41: 289-318, 1991. (Pubitemid 121000771)
29. Diel IJ, Solomayer EF and Bastert G: Biphosphonates and the prevention of metastasis: first eveidences from preclinical and clinical studies. Cancer 88(12 Suppl): 3080-3088, 2000. (Pubitemid 30413194)
30. Senaratne SG, Pirianov G, Mansi JL, Arnett TR and Colston KW: Biphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468, 2000. (Pubitemid 30175914)
31. Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V, Tagliaferri P and Venuta S: Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 14: 841-844, 2000. (Pubitemid 30235061)
32. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP and Wilhelm M: Stimulation of gamma/delta T-cells by aminobiphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96: 384-392, 2000. (Pubitemid 30463353)
33. Green JR: Antitumor potential of biphosphonates. Med Klin 95(2 Suppl): 23-28, 2000.
34. van Beek E, Pieterman E, Cohen L, Lowik C and Papapoulos S: Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing biphosphonates. Biochem Biophys Res Commun 264(1): 108-111, 1999. (Pubitemid 29500472)
35. Glomset JA, Gelb MH and Farnsworth CC: Geranylgeranylated proteins. Biochem Soc Trans 20(2): 479-484, 1992.
36. Notarnicola M, Messa C, Cavallini A, Bifulco M, Tecce MF, Eletto D, Di Leo A, Montemurro S, Laezza C and Caruso MG: Higher farnesyl diphosphate synthase activity in human colorectal cancer: inhibition of cellular apoptosis. Oncology 67: 351-358, 2004.
37. Sung YK, Hwang SY, Park MK, Farooq M, Han IS, Bae HI, Kim JC and Kim M: Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 94: 259-262, 2003. (Pubitemid 36575892)
38. Jiang F, Yang L, Cai X, Cyriac J, Shechter I and Wang Z: Farnesyl diphosphate synthase is abundantly expressed and regulated by androgen in rat prostatic epithelial cells. J Steroid Biochem Mol Biol 78: 123-130, 2001. (Pubitemid 32879327)
39. Rashid A, Pizer ES, Moga M, Milgraum LZ, Zahurak M, Pastermack GR, Kuhajda FP and Hamilton SR: Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. American J Pathol 150: 201-208, 1997. (Pubitemid 27027110)
40. Kuhajda FP: Fatty acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16: 202-208, 2000.
41. Kim EK, Miller I, Landree LE, Borisy-Rudin FF, Brown P, Tihan T, Townsend CA, Witters LA, Moran TH, Kuhajda FP and Ronnett GV: Expression of FAS within hypothalamic neurons: a model for decreased food intake after c75 treatment. Am J Physiol Endocrinol Metab 283: E867-E879, 2002. (Pubitemid 35221365)
42. Pizer ES, Kurman RJ, Pastenack GR and Kuhajda FP: Expression of fatty acid synthase is closely linked to proliferation and stromal decidualization in cycling endometrium. Int J Gynecol Pathol 16: 45-51, 1997. (Pubitemid 27199585)
43. Wilentz R, Witters LA and Pizer E: Lipogenic enzyme fatty acid synthase and acetyl-CoA carboxylase are co-expressed with sterol regulatory element binding protein and Ki-67 in fetal tissue. Pediatr Dev Pathol 3: 525-531, 2000.
44. Jackowski S, Wang J and Baburina I: Activity of the phosphatidylcholine biosynthetic pathway modulates the distribution of fatty acids into glycerolipids in proliferating cells. Biochem Biophys Acta 1483: 301-315, 2000. (Pubitemid 30077493)
45. Chalbos D, Chambon M, Aohaud G and Rochefort H: Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J Biol Chem 262: 9923-9926, 1987.
46. Swinnen JV, Heemers H, Deboel L, Foufelle F, Heyns W and Verhoeven G: Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene 19: 5173-5181, 2000.
47. Kuhajda FP, Piantadosl S and Pasternack GR: Hepatoglobin-related protein (HPR) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 321: 636-641, 1989. (Pubitemid 19221307)
48. Alo P, Visca P, Marci A, Mangoni A, Botti C and Di Tondo U: Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77: 474-482, 1996. (Pubitemid 26047568)
49. Lu S, Zhang X, Badawi AF, El-Sohemy A and Archer MC: Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Lett 184: 7-12, 2002. (Pubitemid 34718101)
50. Lu S and Archer MC: Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer. Carcinogenesis 26: 153-157, 2005. (Pubitemid 40207710)
51. Visca P, Alo PL, Del Nonno F, Botti C, Trombetta G, Marandino F, Filippi S, Di Tondo U and Donnorso RP: Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in nonneoplastic mucosa. Clin Cancer Res 5: 4111-4118, 1999. (Pubitemid 30013793)
52. Chelbos D, Joyeux C, Galtier F and Rochefort H: Progestin-induced fatty acid synthesase in breast cancer: from molecular biology to clinical applications. Ann NY Acad Sci 595: 67-73, 1990. (Pubitemid 20282940)
53. Notarnicola M, Altomare DF, Calvani M, Orlando A, Bifulco M, D'Attoma B and Caruso MG: Fatty acid synthase hyperactivation in human colorectal cancer: relationship with tumor side and sex. Oncology 71: 327-332, 2007. (Pubitemid 47573693)
54. Messa C, Russo F, Caruso MG and Di Leo A: EGF, TGF-α and EGF-R in human colorectal adenocarcinoma. Acta Oncologica 37: 285-289, 1998. (Pubitemid 28307854)
55. Pascal G, Bouzourene H, Cerottini JP, Chaubert P, Benhattar J, Secic M, Wexner S, Givel JC and Belin B: Dukes B colorectal cancer. Distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 44: 364-373, 2001. (Pubitemid 32226325)
56. Swinnen JV, Vanderhoydonc F, Elgamal AA, Eelen M, Vercaeren I, Joniau S, Van Poppel H, Baert L, Goossens K, Heyns W and Verhoeven G: Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 88: 176-179, 2000.
57. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S and Loda M: Fatty acid expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1: 707-715, 2003. (Pubitemid 37025589)
58. Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF and Pizer ES: Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulates by p53. Cancer Res 61: 1493-1499, 2001. (Pubitemid 34292578)
59. Notarnicola M, Pisanti S, Tutino V, Bocale D, Rotelli MT, Gentile A, Memeo V, Bifulco M, Perri E and Caruso MG: Effects of olive oil polyphenols on fatty acid synthase gene expression and activity in human colorectal cancer cells. Genes Nutr 6(1): 63-69, 2011.
60. Gill CI, Boyd A, McDermott E, McCann M, Servili M, Selvaggini R, Taticchi A, Esposto S, Montedoro G, McGlynn H and Rowland I: Potential anticancer effects of virgin olive phenols on colorectal carcinogenesis models in vitro. Int J Cancer 117: 1-7, 2005. (Pubitemid 41262753)
61. Obied HK, Prenzler PD, Konczak I, Rheman A and Robard K: Chemistry and bioactivity of olive biophenols in some antioxidant and antiproliferative "in vitro" bioassays. Chem Res Toxicol 22: 227-234, 2009.
62. Fini L, Hotchkiss E, Fogliano V, Graziani G, Romano M, De Vol EB, Qin H, Selgrad M, Boland CR and Ricciardiello L: Chemopreventive properties of pinoresinol-rich olive oil involve a selective activation of the ATM-p53 cascade in colon cancer cell lines. Carcinogenesis 29: 139-146, 2008. (Pubitemid 351201752)
63. Owen RW, Giacosa A, Hull WE, Haubner R, Wurtele G, Spiegelhalder and Bartsch H: Olive-oil consumption and health: the possible role of antioxidants. Lancet Oncology 1: 107-112, 2000.
64. Notarnicola M, Tutino V, Calvani M, Lorusso D, Guerra V and Caruso MG: Serum levels of Fatty acid synthase in colorectal cancer are associated with tumor stage. J Gastrointestinal Cancer 2011, DOI: 10.1007/s12029-011-9300-2
65. Wang Y, Kuhajda FP, Li JN, Pizer ES, Han WF, Sokoll LJ and Chan DW: Fatty acid synthase expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett 167: 99-104, 2001. (Pubitemid 32373274)
66. Walter K, Hong S-M, Nyhan S, Canto M, Fedarko N, Klein A, Griffith M, Omura N, Medghalchi S, Kuhajda F and Goggins M: Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev 18(9): 2380-2385, 2009.
67. Vazquez-Martin A, Fernandez-Real JM, Oliveras-Ferraros C, Navarrete JM, Martin-Castillo B, Del Barco S, Brunet J and Menendez JA: Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. Int J Oncology 35: 1369-1376, 2009.
68. Wang Y, Kuhajda FP, Li J, Finch TT, Cheng P, Koh C, Li T, Sokoll LJ and Chan DW: Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer. J Exp Ther Oncol 4: 101-110, 2004. (Pubitemid 39079046)
69. Bianchini F, Kaaks R and Vainio H: Overweight, obesity and cancer risk. Lancet Oncology 3: 565-574, 2002.
70. Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348: 1625-1638, 2003. (Pubitemid 36459468)
71. Calle EE and Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4: 579-591, 2004. (Pubitemid 39025053)
72. Amemori S, Ootani A, Aoki S, Fujise T, Shimoda R, Kakimoto T, Shiraishi R, Sakata Y, Tsunada S, Iwakiri R and Fujimoto K: Adipocytes and preadipocytes promote the proliferation of colon cancer cells "in vitro". Am J Physiol Gastrointest Liver Physiol 292: G923-G929, 2007.
73. Cerne D, Zitnik IP and Sok M: Increased fatty acid synthase activity in non-small cell lung cancer tissue is a weaker predictor of shorter patient survival than increased lipoprotein lipase activity. Arch Med Res 41: 405-409, 2010.
74. Trost Z, Sok M, Marc J and Cerne D: Increased lipoprotein lipase activity in non-small cell lung cancer tissue predicts shorter patient survival. Arch Med Res 40: 364-368, 2009.
75. Notarnicola M, Miccolis A, Tutino V, Lorusso D and Caruso MG: Low levels of lipogenic enzymes in peritumoral adipose tissue of colorectal cancer patients. Lipids 47(1): 59-63, 2012.